(Q34660065)

3 August 2017

1 reference

title

Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists (English)

1 reference

3 August 2017

S Oparil

1

1 reference

3 August 2017

1 May 2002

1 reference

Journal of Human Hypertension

3 August 2017

1 reference

3 August 2017

16 Suppl 2

1 reference

3 August 2017

S17-23

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1001394

3 August 2017

0 references

cites work

Fifty years of Framingham Study contributions to understanding hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Renoprotection and renin-angiotensin system blockade in diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Regression of left ventricular hypertrophy in human hypertension with irbesartan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Inadequate Management of Blood Pressure in a Hypertensive Population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. The Treatment of Mild Hypertension Research Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Effects of losartan on hypertension and left ventricular mass: a long-term study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesar

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001394

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1001394

1 reference

PubMed ID

12035749

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

12035749